HIMS ends compounded Semaglutide offering
Hims announces it will stop providing compounded Semaglutide, after removal from the FDA shortage list.
With the recent announcement of Semaglutide leaving the FDA shortage list:
Semaglutide removed from shortage list
It happened sooner than we expected -- the FDA has announced Semaglutide shortage resolution, removing it from the shortage list.
GLP1.Guide Staff
Companies are already starting to change their offering with regards to compounded GLP1 Receptor Agonists.
HIMS has announced that they will ultimately stop offering compounded Semaglutide to their customers.
HIMS began selling compounded Semaglutide only in May 2024, so not even a year has passed before they began offering compounded GLP1s.
Want to read about what HIMS will offer instead? The rest of this article is no longer available for free – if you'd like to read the rest of our analysis, check us out on Substack:
